Egnach, July 23, 2025 – Resaphene Suisse AG is confirmed in its innovative approach to tinnitus treatment by current clinical studies. While conventional therapies often only provide symptomatic relief, the company pursues a holistic approach with the product tinniwell : a combination of individual audiotherapy, heat treatment, and jaw relaxation.

According to a current meta-study by the European Tinnitus Association (ETA) more than 80% of those affected need a multimodal therapy form that considers both neural and muscular influencing factors. This is precisely where tinniwell comes in:

• The personalized audio frequency therapy specifically stimulates the affected hearing areas in the brain.

• Integrated heat application helps to relieve tension in the jaw and neck area.

• According to user feedback, regular application can significantly reduce subjective complaints.

"We are pleased about the growing recognition from scientific institutions that confirm our therapy strategy," said Thomas Rauterkus, Chief Medical Officer of Resaphene Suisse AG. "tinniwell is more than a device – it is a new way of dealing with chronic tinnitus."

The company plans to collaborate with European ENT centers for further multicenter studies to evaluate long-term therapy effects.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company founded in 2015 that has been distributing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG

Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 71 510 07 24
a.rauterkus@resaphene.ch